Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells

Yun-Fang Zhen1, Song-Tao Li2, Yun-Rong Zhu3

  • 1The Center of Diagnosis and Treatment for Children's Bone Diseases, The Children's Hospital Affiliated to Soochow University, Suzhou, China.

Oncotarget
|October 22, 2016
PubMed

Insights

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) drives resistance to salinomycin in osteosarcoma. Inhibiting DNA-PKcs enhances salinomycin

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Osteosarcoma (OS) remains a significant challenge, necessitating novel therapeutic agents.
  • Salinomycin has emerged as a potential anti-OS agent.
  • Understanding resistance mechanisms is crucial for optimizing OS treatment.

Purpose of the Study:

  • To identify key factors mediating resistance to salinomycin in osteosarcoma cells.
  • To investigate the role of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) in salinomycin resistance.
  • To explore therapeutic strategies combining salinomycin with DNA-PKcs inhibition.

Main Methods:

  • Utilized osteosarcoma cell lines (U2OS, MG-63) and in vivo xenograft models.
  • Employed DNA-PKcs inhibitors (NU7026, NU7441, LY294002), shRNA knockdown, and microRNA-101 (miR-101) expression.
  • Assessed cell death, apoptosis, autophagy markers (Beclin-1), and tumor growth.

Main Results:

  • DNA-PKcs was identified as a primary salinomycin resistance factor in OS cells.
  • Inhibition or knockdown of DNA-PKcs potentiated salinomycin-induced cell death and apoptosis.
  • DNA-PKcs inhibition suppressed salinomycin-induced pro-survival autophagy.
  • Combined salinomycin and DNA-PKcs inhibitor treatment reduced tumor growth in vivo.

Conclusions:

  • DNA-PKcs is a critical mediator of salinomycin resistance in osteosarcoma.
  • Targeting DNA-PKcs can overcome salinomycin resistance and enhance its anti-tumor efficacy.
  • Combination therapy with salinomycin and DNA-PKcs inhibitors holds promise for osteosarcoma treatment.